Global Blood and Plasma Components Market 2023-2029

March 2023 | 64 pages | ID: GDC33BCEB909EN
Gen Consulting Company

Abstracts

Blood and plasma components are the individual parts of blood and plasma that are used for various medical procedures and therapies. According to the latest research, the global blood and plasma components market is poised to grow by USD 14.8 billion during 2023-2029, progressing at a CAGR of 4.82% during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global blood and plasma components market. It presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. The report also identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, application, end user, and region. The global market for blood and plasma components can be segmented by product: plasma-derived products, transfusion. The plasma-derived products segment was the largest contributor to the global blood and plasma components market in 2022. Blood and plasma components market is further segmented by application: hematology, solid tumor management, others. According to the research, the hematology segment had the largest share in the global blood and plasma components market. Based on end user, the blood and plasma components market is segmented into: hospitals and specialty clinics, research institutions, diagnostics laboratories, others. The hospitals and specialty clinics segment held the largest revenue share in 2022. On the basis of region, the blood and plasma components market also can be divided into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. Globally, North America made up the largest share of the blood and plasma components market.

Market Segmentation
By product: plasma-derived products, transfusion
By application: hematology, solid tumor management, others
By end user: hospitals and specialty clinics, research institutions, diagnostics laboratories, others
By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report explores the recent developments and profiles of key vendors in the Global Blood and Plasma Components Market, including CSL Limited, Grifols, S.A., Takeda Pharmaceutical Company Limited, ADMA Biologics Inc., Biologics, Inc., C Pharma (Green Cross Corporation), Emergent BioSolutions, Inc., LFB S.A., among others. In this report, key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Scope of the Report
To analyze and forecast the market size of the global blood and plasma components market.
To classify and forecast the global blood and plasma components market based on product, application, end user, region.
To identify drivers and challenges for the global blood and plasma components market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global blood and plasma components market.
To identify and analyze the profile of leading players operating in the global blood and plasma components market.

Why Choose This Report
Gain a reliable outlook of the global blood and plasma components market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints

PART 5. MARKET BREAKDOWN BY PRODUCT

Plasma-derived products
Transfusion

PART 6. MARKET BREAKDOWN BY APPLICATION

Hematology
Solid tumor management
Others

PART 7. MARKET BREAKDOWN BY END USER

Hospitals and specialty clinics
Research institutions
Diagnostics laboratories
Others

PART 8. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 9. KEY COMPANIES

CSL Limited
Grifols, S.A.
Takeda Pharmaceutical Company Limited
ADMA Biologics Inc.
Biologics, Inc.
C Pharma (Green Cross Corporation)
Emergent BioSolutions, Inc.
LFB S.A.

DISCLAIMER